Concit Pharma has changed its corporate name to Contera Pharma, effective from 19.11.2013.
As of 19.11.2013 Don deBethizy is appointed chairman of the board. Don is the former CEO of Targacept, Inc a public biotech company discovering and developing novel small molecules targeting serious CNS disorders. Don will help the company to explore financing opportunities among investors from his extensive network.
Finn Eggert Sørensen is appointed CBO and responsible for exploring future partnering and financing opportunities for JM-010 in the Pharma and Biotech community using his extensive network. Finn is the former CBO of NeuroSearch.
As of 19.11.2013 Contera Pharma has raised new capital from current investors and the current investors have committed themselves to participate in the Series A financing round.
Contera Pharma has developed a unique approach of using a combination therapy to tackle two clinically relevant synergistic pathways to obtain strong therapeutic effects. The Contera Pharma approach will generate new safe and efficacious therapeutic entities based on robust pre-clinical and clinical evidence. It will secure fast access to human proof of concept data, low risk of attrition in development and long exclusivity. JM-010 that is designed through this technology has the potential to create a breakthrough in the treatment of movement disorders caused by current treatment paradigms for Parkinson’s disease and schizophrenia.
The new name reflects our new identity with a new vision, new achievements, new organisation and new financing.
